The firm owned 164,798 shares of the company's stock after acquiring an additional 56,363 shares during the period. Jefferies has "Buy" rating and $42.0 target.
Intellia Therapeutics Inc. (NASDAQ:NTLA) received a Buy rating from 0 analysts. The company reported revenue of $5.38 Million in the same period a year ago. Finally, TheStreet upgraded shares of Intellia Therapeutics from a "d+" rating to a "c-" rating in a report on Thursday, July 6th.
Why to Observe Volume of Intellia Therapeutics Inc. Barclays PLC initiated coverage on shares of Intellia Therapeutics in a research note on Wednesday, September 6th. The company presently has an average rating of "Hold" and an average target price of $29.50.
The consensus recommendation, according to Zacks Investment research, is 1.4. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock.
NTLA is now undervalued by -24.54% relative to the average 1-year price target of $27.83 taken from a group of Wall Street Analysts. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and worldwide copyright & trademark laws. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and worldwide copyright and trademark law.
According to the latest data, investors are looking at Intellia Therapeutics Inc.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Tuesday, October 31st.
The market capitalization (Stock Price Multiply by Total Number of Outstanding Shares) for the company is reported at $724.50M. Intellia Therapeutics had a negative return on equity of 27.19% and a negative net margin of 215.92%.
Analysts believe that the company has the potential to earn average revenue of $5.88 Million for the current quarter.
For the current quarter, 5 analysts are projecting a mean EPS of $-0.5/share. The company's quarterly revenue was up 49.0% compared to the same quarter past year.
Institutional investors and hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP bought a new position in Intellia Therapeutics in the 2nd quarter worth about $907,000. (NTLA), 6 have Buy rating, 0 Sell and 2 Hold. The original version of this news story can be accessed at https://weekherald.com/2017/11/02/intellia-therapeutics-inc-to-post-fy2017-earnings-of-1-71-per-share-oppenheimer-holdings-forecasts-ntla.html. Bank of Montreal Can increased its position in Intellia Therapeutics by 1,031.7% in the second quarter. ARK Investment Management LLC grew its position in Intellia Therapeutics by 118.9% in the 2nd quarter. Finally, State Street Corp boosted its position in Intellia Therapeutics by 52.0% in the second quarter. A sudden increase in a stock's activity can be a sign that investors are trading in anticipation of a catalyst, or that investors feel very strongly in one way or the other about the future direction of a stock. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence.
Sentiment Report: Advance Auto Parts Inc (NYSE:AAP)
The Davidson Kempner Capital Management Lp holds 187,500 shares with $21.86M value, up from 150,000 last quarter. Check Point Software Technologies Ltd. (NASDAQ:CHKP) has risen 31.64% since November 2, 2016 and is uptrending.